London, United Kingdom and Newport Beach, California - October 8 2026 Sage Healthcare Ltd ("Sage") and Roth Capital Partners, LLC ("Roth") have announced a strategic collaboration to identify and assess European healthcare and life-science companies that may benefit from experienced transaction advice and U.S. capital markets expertise. Sage will contribute access to its European network, transaction experience and SAGEIQ™, its AI-enabled company identification and prioritisa

Sage acted as transaction adviser to PolyPid on the North American commercialisation agreement LONDON, 3 September 2026 Sage is a specialist global life-sciences transaction advisory firm, is pleased to confirm that it acted as transaction adviser to PolyPid Ltd. (Nasdaq: PYPD) in connection with its exclusive commercial partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada for the prevention of abdominal colorectal su

Late-stage oral therapy designed to reduce bacterial exacerbations, hospital admissions and the healthcare burden of COPD Melbourne, Australia; New York, USA; and London, UK – XX June 2026 – Respien Pty Ltd (“Respien”), an Australian biopharmaceutical company developing novel respiratory therapies, has appointed Sage Healthcare Ltd and The Sage Group Inc. (collectively “Sage”) to lead a global partnering process for HI-164, Respien’s lead Phase 3-ready respiratory asset. HI-1

Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquir

EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo DENVER, CO / ACCESS Newswire / December 15, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a

Manassas, VA - Serpin Pharma is pleased to announce a strategic partnership with Dogwood Therapeutics to develop and commercialize SP16,...

Aytu BioPharma Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics,...

Sage Group's new client, Notogen, is a US registered company focused on a regenerative therapeutic, designated NTG-101, for treating chronic back and neck pain caused by degenerating spinal discs (eg Degenerative Disc Disease, DDD). NTG-101 is available for licensing, strategic partnering or acquisition. NTG-101 is protein-based biologic designed to mediate the progression of spinal disc degeneration disease (DDD) and induce a restorative effect. NTG-101 is an intradiscal mol